Thyrocare announces dividend, bonus shares amid strong Q2 growth

Thyrocare Technologies Limited reported robust financial performance for the quarter and half year ended September 30, 2025. Consolidated revenue grew 22% year-over-year to INR 217 Cr, and normalized EBITDA increased 49% to INR 75.36 Cr. Standalone revenue also saw a 24% rise to INR 202 Cr, contributing to a 46% jump in standalone profit after tax. The company's pathology revenue grew 24% year-over-year, driven by a 20% increase in franchise revenue and a 35% increase in partnership revenue.

In a key development, the board approved an interim dividend of INR 7/- per equity share for FY2025-26, representing 70% of the face value. Additionally, in celebration of its silver jubilee and upcoming Diwali festivities, the company recommended a 2:1 bonus share issue, capitalizing up to INR 106.11 Crores from reserves. This move is subject to shareholder and regulatory approvals, with bonus shares expected to be credited within two months of board approval.

Thyrocare also announced an increase in its authorized share capital from INR 1,00,00,00,000 to INR 3,00,00,00,000 and the re-appointment of M/s. Ernst & Young as internal auditors for FY2025-26. These strategic decisions reflect the company's commitment to enhancing shareholder value and strengthening its operational footprint, including the commissioning of a new regional processing lab in Vijaywada.